Human EGFRvIII Protein, His Tag, low endotoxin (MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
EGI-H52H4-50ug
$420.00
EGI-H52H4-1mg (500ug X 2)
$2495.00
ETA of in-stock products:2 business days

Product Details

  • Synonyms

    EGFRvIII

  • Source

    Human EGFRvIII, His Tag (EGI-H52H4) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1).

    Predicted N-terminus: Leu 25

    Request for sequence
  • Molecular Characterization

    EGFRvIII Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 40.5 kDa. The protein migrates as 55-80 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 0.01 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    EGFRvIII SDS-PAGE

    Human EGFRvIII, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    EGFRvIII SEC-MALS

    The purity of Human EGFRvIII, His Tag (Cat. No. EGI-H52H4) is more than 95% and the molecular weight of this protein is around 50-70 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     EGFRvIII ELISA

    Immobilized Human EGFRvIII, His Tag (Cat. No. EGI-H52H4) at 1 μg/mL (100 μL/well) can bind Anti-EGFRvIII Antibody , Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

    Protocol
  •  EGFRvIII ELISA

    Immobilized Human EGFRvIII, His Tag (Cat. No. EGI-H52H4) at 1 μg/mL (100 μL/well) can bind Cetuximab with a linear range of 0.1-1 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     EGFRvIII SPR

    Anti-EGF R antibody captured on Protein A Chip can bind Human EGFRvIII, His Tag (Cat. No. EGI-H52H4) with an affinity constant of 1.42 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  • Bioactivity-FACS

     EGFRvIII FACS

    2e5 of anti-EGFRvIII CAR-293 cells were stained with 100 μL of 3 μg/mL of Human EGFRvIII, His Tag (Cat. No. EGI-H52H4) and negative control protein respectively, washed and then followed by PE anti-His Tag antibody and analyzed with FACS (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.

Recent Advances

 
Drug Development Progress
  • English Name:

    Epidermal growth factor receptor variant III

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    14 Details

  • Highest Development Stage:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background